Skip to main content

Advertisement

SpringerLink
Log in

Update: Innate Lymphoid Cells in Inflammatory Bowel Disease

  • Review
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Inflammatory bowel disease (IBD) is a chronic and nonspecific intestinal inflammatory condition with high relapse rate. Its pathogenesis has been linked to dysbacteriosis, genetic and environmental factors. In recent years, a new type of lymphocytes, termed innate lymphoid cells, has been described and classified into three subtypes of innate lymphoid cells—group 1, group 2 and group 3. An imbalance among these subsets’ interaction with gut microbiome, and other immune cells affects intestinal mucosal homeostasis. Understanding the role of innate lymphoid cells may provide ideas for developing novel and targeted approaches for treatment of IBD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Liu TC, Stappenbeck TS. Genetics and pathogenesis of inflammatory bowel disease. Annu Rev Pathol. 2016;11:127–148

    CAS  PubMed  PubMed Central  Google Scholar 

  2. Peloquin JM, Goel G, Villablanca EJ, Xavier RJ. Mechanisms of pediatric inflammatory bowel disease. Annu Rev Immunol. 2016;34:31–64

    CAS  PubMed  Google Scholar 

  3. Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel J-F. Ulcerative colitis. Lancet. 2017;389:1756–1770

    PubMed  Google Scholar 

  4. Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L. Crohn’s disease. Lancet (London, England). 2017;389:1741–1755

    Google Scholar 

  5. Uhlig HH, Powrie F. Translating immunology into therapeutic concepts for inflammatory bowel disease. Annu Rev Immunol. 2018;36:755–781

    CAS  PubMed  Google Scholar 

  6. de Souza HSP, Fiocchi C, Iliopoulos D. The IBD interactome: an integrated view of aetiology, pathogenesis and therapy. Nat Rev Gastroenterol Hepatol. 2017;14:739–749

    PubMed  Google Scholar 

  7. Breese EB, Corrigan CP, Walker-Smith CJ, MacDonald JA. Interleukin-2- and interferon-gamma-secreting T cells in normal and diseased human intestinal mucosa. Immunology. 1993;78:127–131

    CAS  PubMed  PubMed Central  Google Scholar 

  8. Rovedatti L, Kudo T, Biancheri P et al. Differential regulation of interleukin 17 and interferon gamma production in inflammatory bowel disease. Gut. 2009;58:1629–1636

    CAS  PubMed  Google Scholar 

  9. Liu H, Dasgupta S, Fu Y et al. Subsets of mononuclear phagocytes are enriched in the inflamed colons of patients with IBD. BMC Immunol. 2019;20:42

    PubMed  PubMed Central  Google Scholar 

  10. Park JH, Jeong DY, Peyrin-Biroulet L, Eisenhut M, Shin JI. Insight into the role of TSLP in inflammatory bowel diseases. Autoimmun Rev. 2017;16:55–63

    CAS  PubMed  Google Scholar 

  11. Giuffrida P, Caprioli F, Facciotti F, Di Sabatino A. The role of interleukin-13 in chronic inflammatory intestinal disorders. Autoimmun Rev. 2019;18:549–555

    CAS  PubMed  Google Scholar 

  12. Ealey KN, Koyasu S. How many subsets of innate lymphoid cells do we need? Immunity. 2017;46:10–13

    CAS  PubMed  Google Scholar 

  13. Simoni Y, Newell EW. Dissecting human ILC heterogeneity: more than just three subsets. Immunology. 2018;153:297–303

    CAS  PubMed  Google Scholar 

  14. Giuffrida P, Corazza GR, Di Sabatino A. Old and new lymphocyte players in inflammatory bowel disease. Dig Dis Sci. 2018;63:277–288. https://doi.org/10.1007/s10620-017-4892-4

    Article  CAS  PubMed  Google Scholar 

  15. Cupedo T, Crellin NK, Papazian N et al. Human fetal lymphoid tissue-inducer cells are interleukin 17-producing precursors to RORC+ CD127+ natural killer-like cells. Nat Immunol. 2009;10:66–74

    CAS  PubMed  Google Scholar 

  16. Cella M, Fuchs A, Vermi W et al. A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity. Nature. 2009;457:722–725

    CAS  PubMed  Google Scholar 

  17. Mebius RE, Rennert P, Weissman IL. Developing lymph nodes collect CD4+CD3- LTbeta+ cells that can differentiate to APC, NK cells, and follicular cells but not T or B cells. Immunity. 1997;7:493–504

    CAS  PubMed  Google Scholar 

  18. Huang Y, Mao K, Germain RN. Thinking differently about ILCs-Not just tissue resident and not just the same as CD4(+) T-cell effectors. Immunol Rev. 2018;286:160–171

    CAS  PubMed  PubMed Central  Google Scholar 

  19. Trabanelli S, Gomez-Cadena A, Salomé B et al. Human innate lymphoid cells (ILCs): Toward a uniform immune-phenotyping. Cytometry B Clin. Cytometry. 2018;94:392–399

    CAS  PubMed  Google Scholar 

  20. Panda SK, Colonna M. Innate lymphoid cells in mucosal immunity. Front Immunol. 2019;10:861

    CAS  PubMed  PubMed Central  Google Scholar 

  21. Sonnenberg GF, Hepworth MR. Functional interactions between innate lymphoid cells and adaptive immunity. Nat Rev Immunol. 2019;19:599–613

    CAS  PubMed  PubMed Central  Google Scholar 

  22. Spits H, Artis D, Colonna M et al. Innate lymphoid cells: a proposal for uniform nomenclature. Nat Rev Immunol. 2013;13:145–149

    CAS  PubMed  Google Scholar 

  23. Zook EC, Kee BL. Development of innate lymphoid cells. Nat Immunol. 2016;17:775–782

    CAS  PubMed  Google Scholar 

  24. Lim AI, Verrier T, Vosshenrich CAJ, Di Santo JP. Developmental options and functional plasticity of innate lymphoid cells. Curr. Opin. Immunol. 2017;44:61–68

    CAS  PubMed  Google Scholar 

  25. Eberl G, Colonna M, Di Santo JP, McKenzie ANJ. Innate lymphoid cells: a new paradigm in immunology. Science. 2015;348:6566

    Google Scholar 

  26. Zhang J, Marotel M, Fauteux-Daniel S et al. T-bet and Eomes govern differentiation and function of mouse and human NK cells and ILC1. Eur J Immunol. 2018;48:738–750

    CAS  PubMed  Google Scholar 

  27. Poggi A, Benelli R, Vene R et al. Human gut-associated natural killer cells in health and disease. Front Immunol. 2019;10:961

    CAS  PubMed  PubMed Central  Google Scholar 

  28. Bernink JH, Peters CP, Munneke M et al. Human type 1 innate lymphoid cells accumulate in inflamed mucosal tissues. Nat Immunol. 2013;14:221–229

    CAS  PubMed  Google Scholar 

  29. Fuchs A, Vermi W, Lee JS et al. Intraepithelial type 1 innate lymphoid cells are a unique subset of IL-12- and IL-15-responsive IFN-gamma-producing cells. Immunity. 2013;38:769–781

    CAS  PubMed  PubMed Central  Google Scholar 

  30. Hwang YY, McKenzie AN. Innate lymphoid cells in immunity and disease. Adv Exp Med Biol. 2013;785:9–26

    CAS  PubMed  Google Scholar 

  31. Prager I, Watzl C. Mechanisms of natural killer cell-mediated cellular cytotoxicity. J Leukoc Biol. 2019;105:1319–1329

    CAS  PubMed  Google Scholar 

  32. Campos TM, Novais FO, Saldanha M, et al. Granzyme B produced by natural killer cells enhances inflammatory response and contributes to the immunopathology of cutaneous leishmaniasis. J Infect Dis. 2019.

  33. Klein Wolterink RG, Serafini N, van Nimwegen M et al. Essential, dose-dependent role for the transcription factor Gata3 in the development of IL-5+ and IL-13+ type 2 innate lymphoid cells. Proc Natl Acad Sci USA 2013;110:10240–10245

    PubMed  PubMed Central  Google Scholar 

  34. Hoyler T, Klose Christoph SN, Souabni A et al. The transcription factor GATA-3 controls cell fate and maintenance of type 2 innate lymphoid cells. Immunity. 2012;37:634–648

    CAS  PubMed  PubMed Central  Google Scholar 

  35. Spooner CJ, Lesch J, Yan D et al. Specification of type 2 innate lymphocytes by the transcriptional determinant Gfi1. Nat Immunol. 2013;14:1229–1236

    CAS  PubMed  Google Scholar 

  36. Yu Y, Wang C, Clare S et al. The transcription factor Bcl11b is specifically expressed in group 2 innate lymphoid cells and is essential for their development. J Exp Med. 2015;212:865–874

    CAS  PubMed  PubMed Central  Google Scholar 

  37. Kim BS, Wojno ED, Artis D. Innate lymphoid cells and allergic inflammation. Curr Opin Immunol. 2013;25:738–744

    CAS  PubMed  PubMed Central  Google Scholar 

  38. Jiang M, Tao S, Zhang S et al. Type 2 innate lymphoid cells participate in IL-33-stimulated Th2-associated immune response in chronic obstructive pulmonary disease. Exp Ther Med. 2019;18:3109–3116

    CAS  PubMed  PubMed Central  Google Scholar 

  39. Helfrich S, Mindt BC, Fritz JH, Duerr CU. Group 2 innate lymphoid cells in respiratory allergic inflammation. Front Immunol. 2019;10:930

    CAS  PubMed  PubMed Central  Google Scholar 

  40. Herbert DR, Douglas B, Zullo K. Group 2 innate lymphoid cells (ILC2): type 2 immunity and helminth immunity. Int J Mol Sci. 2019;20:2276

    CAS  PubMed Central  Google Scholar 

  41. Rafei-Shamsabadi DA, Klose CSN, Halim TYF, Tanriver Y, Jakob T. Context dependent role of type 2 innate lymphoid cells in allergic skin inflammation. Front Immunol. 2019;10:2591

    CAS  PubMed  PubMed Central  Google Scholar 

  42. Qiu J, Heller JJ, Guo X et al. The aryl hydrocarbon receptor regulates gut immunity through modulation of innate lymphoid cells. Immunity. 2012;36:92–104

    CAS  PubMed  Google Scholar 

  43. Britanova L, Diefenbach A. Interplay of innate lymphoid cells and the microbiota. Immunol Rev. 2017;279:36–51

    CAS  PubMed  Google Scholar 

  44. Reboldi A, Arnon TI, Rodda LB, Atakilit A, Sheppard D, Cyster JG. IgA production requires B cell interaction with subepithelial dendritic cells in Peyers patches. Science. 2016;352:4822

    Google Scholar 

  45. Kruglov AA, Grivennikov SI, Kuprash DV et al. Nonredundant function of soluble LTalpha3 produced by innate lymphoid cells in intestinal homeostasis. Science. 2013;342:1243–1246

    CAS  PubMed  Google Scholar 

  46. Takatori H, Kanno Y, Watford WT et al. Lymphoid tissue inducer-like cells are an innate source of IL-17 and IL-22. J Exp Med. 2009;206:35–41

    CAS  PubMed  PubMed Central  Google Scholar 

  47. Klose CS, Kiss EA, Schwierzeck V et al. A T-bet gradient controls the fate and function of CCR6-RORgammat+ innate lymphoid cells. Nature. 2013;494:261–265

    CAS  PubMed  Google Scholar 

  48. Mackley EC, Houston S, Marriott CL et al. CCR7-dependent trafficking of RORgamma(+) ILCs creates a unique microenvironment within mucosal draining lymph nodes. Nat Commun. 2015;6:5862

    CAS  PubMed  Google Scholar 

  49. Song C, Lee JS, Gilfillan S et al. Unique and redundant functions of NKp46+ ILC3s in models of intestinal inflammation. J Exp Med. 2015;212:1869–1882

    CAS  PubMed  PubMed Central  Google Scholar 

  50. Zeng B, Shi S, Ashworth G, Dong C, Liu J, Xing F. ILC3 function as a double-edged sword in inflammatory bowel diseases. Cell Death Disease. 2019;10:315

    PubMed  PubMed Central  Google Scholar 

  51. Powell N, Lo JW, Biancheri P et al. Interleukin 6 increases production of cytokines by colonic innate lymphoid cells in mice and patients with chronic intestinal inflammation. Gastroenterology. 2015;149:e15

    Google Scholar 

  52. Pearson C, Thornton EE, McKenzie B et al. ILC3 GM-CSF production and mobilisation orchestrate acute intestinal inflammation. Elife. 2016;5:e10066

    PubMed  PubMed Central  Google Scholar 

  53. Giacomin PR, Moy RH, Noti M et al. Epithelial-intrinsic IKKalpha expression regulates group 3 innate lymphoid cell responses and antibacterial immunity. J Exp Med. 2015;212:1513–1528

    CAS  PubMed  PubMed Central  Google Scholar 

  54. Aparicio-Domingo P, Romera-Hernandez M, Karrich JJ et al. Type 3 innate lymphoid cells maintain intestinal epithelial stem cells after tissue damage. J Exp Med. 2015;212:1783–1791

    CAS  PubMed  PubMed Central  Google Scholar 

  55. Pantazi E, Powell N. Group 3 ILCs: peacekeepers or troublemakers? What’s Your Gut Telling You?! Front Immunol. 2019;10:676

    CAS  PubMed  PubMed Central  Google Scholar 

  56. Gronke K, Hernandez PP, Zimmermann J et al. Interleukin-22 protects intestinal stem cells against genotoxic stress. Nature. 2019;566:249–253

    CAS  PubMed  PubMed Central  Google Scholar 

  57. Geremia A, Arancibia-Carcamo CV, Fleming MP et al. IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease. J Exp Med. 2011;208:1127–1133

    CAS  PubMed  PubMed Central  Google Scholar 

  58. Diefenbach A, Colonna M, Koyasu S. Development, differentiation, and diversity of innate lymphoid cells. Immunity. 2014;41:354–365

    CAS  PubMed  PubMed Central  Google Scholar 

  59. Bernink Jochem H, Krabbendam L, Germar K et al. Interleukin-12 and -23 control plasticity of CD127+ Group 1 and Group 3 innate lymphoid cells in the intestinal lamina propria. Immunity. 2015;43:146–160

    CAS  PubMed  Google Scholar 

  60. Teunissen MBM, Munneke JM, Bernink JH et al. Composition of innate lymphoid cell subsets in the human skin: enrichment of NCR + ILC3 in lesional skin and blood of psoriasis patients. J Invest Dermatol. 2014;134:2351–2360

    CAS  PubMed  Google Scholar 

  61. Viant C, Rankin LC, Girard-Madoux MJ, et al. Transforming growth factor-beta and Notch ligands act as opposing environmental cues in regulating the plasticity of type 3 innate lymphoid cells. Sci Signal. 2016;9:ra46.

  62. Chea S, Perchet T, Petit M, et al. Notch signaling in group 3 innate lymphoid cells modulates their plasticity. Sci Signal. 2016;9:ra45.

  63. Ebbo M, Crinier A, Vely F, Vivier E. Innate lymphoid cells: major players in inflammatory diseases. Nat Rev Immunol. 2017;17:665–678

    CAS  PubMed  Google Scholar 

  64. Lim AI, Menegatti S, Bustamante J et al. IL-12 drives functional plasticity of human group 2 innate lymphoid cells. J Exp Med. 2016;213:569–583

    CAS  PubMed  PubMed Central  Google Scholar 

  65. Li S, Bostick JW, Ye J et al. Aryl Hydrocarbon receptor signaling cell intrinsically inhibits intestinal group 2 innate lymphoid cell function. Immunity. 2018;49:915

    CAS  PubMed  PubMed Central  Google Scholar 

  66. Forkel M, van Tol S, Hoog C, Michaelsson J, Almer S, Mjosberg J. Distinct Alterations in the composition of mucosal innate lymphoid cells in newly diagnosed and established crohn’s disease and ulcerative colitis. J Crohns Colitis. 2019;13:67–78

    PubMed  Google Scholar 

  67. Kinnebrew MA, Buffie CG, Diehl GE et al. Interleukin 23 production by intestinal CD103(+)CD11b(+) dendritic cells in response to bacterial flagellin enhances mucosal innate immune defense. Immunity. 2012;36:276–287

    CAS  PubMed  PubMed Central  Google Scholar 

  68. Goto Y, Obata T, Kunisawa J et al. Innate lymphoid cells regulate intestinal epithelial cell glycosylation. Science. 2014;345:1254009

    PubMed  PubMed Central  Google Scholar 

  69. Tsai PY, Zhang B, He WQ et al. IL-22 upregulates epithelial claudin-2 to drive diarrhea and enteric pathogen clearance. Cell Host Microbe. 2017;21:e4

    Google Scholar 

  70. Kobori A, Yagi Y, Imaeda H et al. Interleukin-33 expression is specifically enhanced in inflamed mucosa of ulcerative colitis. J Gastroenterol. 2010;45:999–1007

    CAS  PubMed  Google Scholar 

  71. Schwartz C, O’Grady K, Lavelle EC, Fallon PG. Interleukin 33: an innate alarm for adaptive responses beyond Th2 immunity-emerging roles in obesity, intestinal inflammation, and cancer. Eur J Immunol. 2016;46:1091–1100

    CAS  PubMed  Google Scholar 

  72. Monticelli LA, Osborne LC, Noti M, Tran SV, Zaiss DM, Artis D. IL-33 promotes an innate immune pathway of intestinal tissue protection dependent on amphiregulin-EGFR interactions. Proc Natl Acad Sci USA 2015;112:10762–10767

    CAS  PubMed  PubMed Central  Google Scholar 

  73. Schiering C, Krausgruber T, Chomka A et al. The alarmin IL-33 promotes regulatory T-cell function in the intestine. Nature. 2014;513:564–568

    CAS  PubMed  PubMed Central  Google Scholar 

  74. Forkel M, van Tol S, Höög C, Michaëlsson J, Almer S, Mjösberg J. Distinct alterations in the composition of mucosal innate lymphoid cells in newly diagnosed and established crohn’s disease and ulcerative colitis. J Crohns Colitis. 2019;13:67–78

    PubMed  Google Scholar 

  75. Camelo A, Barlow JL, Drynan LF et al. Blocking IL-25 signalling protects against gut inflammation in a type-2 model of colitis by suppressing nuocyte and NKT derived IL-13. J Gastroenterol. 2012;47:1198–1211

    CAS  PubMed  PubMed Central  Google Scholar 

  76. Zelante T, Iannitti RG, Cunha C et al. Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22. Immunity. 2013;39:372–385

    CAS  PubMed  Google Scholar 

  77. Qiu J, Guo X, Chen ZM et al. Group 3 innate lymphoid cells inhibit T-cell-mediated intestinal inflammation through aryl hydrocarbon receptor signaling and regulation of microflora. Immunity. 2013;39:386–399

    CAS  PubMed  Google Scholar 

  78. Ganal-Vonarburg SC, Duerr CU. The interaction of intestinal microbiota and innate lymphoid cells in health and disease throughout life. Immunology. 2020;159:39–51

    CAS  PubMed  Google Scholar 

  79. Constantinides MG. Interactions between the microbiota and innate and innate-like lymphocytes. J Leukoc Biol. 2018;103:409–419

    CAS  PubMed  Google Scholar 

  80. Blander JM, Longman RS, Iliev ID, Sonnenberg GF, Artis D. Regulation of inflammation by microbiota interactions with the host. Nat Immunol. 2017;18:851–860

    CAS  PubMed  PubMed Central  Google Scholar 

  81. Thaiss CA, Zmora N, Levy M, Elinav E. The microbiome and innate immunity. Nature. 2016;535:65–74

    CAS  PubMed  Google Scholar 

  82. Sawa S, Lochner M, Satoh-Takayama N et al. RORgammat+ innate lymphoid cells regulate intestinal homeostasis by integrating negative signals from the symbiotic microbiota. Nat Immunol. 2011;12:320–326

    CAS  PubMed  Google Scholar 

  83. Sonnenberg GF, Monticelli LA, Alenghat T et al. Innate lymphoid cells promote anatomical containment of lymphoid-resident commensal bacteria. Science. 2012;336:1321–1325

    CAS  PubMed  PubMed Central  Google Scholar 

  84. Penny HA, Hodge SH, Hepworth MR. Orchestration of intestinal homeostasis and tolerance by group 3 innate lymphoid cells. Semin Immunopathol. 2018;40:357–370

    CAS  PubMed  PubMed Central  Google Scholar 

  85. Castleman MJ, Dillon SM, Purba CM et al. Commensal and pathogenic bacteria indirectly induce IL-22 but Not IFNgamma production from human colonic ILC3s via multiple mechanisms. Front Immunol. 2019;10:649

    CAS  PubMed  PubMed Central  Google Scholar 

  86. Babu ST, Niu X, Raetz M, Savani RC, Hooper LV, Mirpuri J. Maternal high-fat diet results in microbiota-dependent expansion of ILC3s in mice offspring. JCI Insight. 2018;3.

  87. Zhou L, Chu C, Teng F et al. Innate lymphoid cells support regulatory T cells in the intestine through interleukin-2. Nature. 2019;568:405–409

    CAS  PubMed  PubMed Central  Google Scholar 

  88. Wang Y, Kuang Z, Yu X, Ruhn KA, Kubo M, Hooper LV. The intestinal microbiota regulates body composition through NFIL3 and the circadian clock. Science. 2017;357:912–916

    CAS  PubMed  PubMed Central  Google Scholar 

  89. Godinho-Silva C, Domingues RG, Rendas M, et al. Light-entrained and brain-tuned circadian circuits regulate ILC3s and gut homeostasis. Nature. 2019.

  90. Teng F, Goc J, Zhou L, et al. A circadian clock is essential for homeostasis of group 3 innate lymphoid cells in the gut. Sci Immunol. 2019;4.

  91. von Moltke J, Ji M, Liang HE, Locksley RM. Tuft-cell-derived IL-25 regulates an intestinal ILC2-epithelial response circuit. Nature. 2016;529:221–225

    Google Scholar 

  92. Frisbee AL, Saleh MM, Young MK et al. IL-33 drives group 2 innate lymphoid cell-mediated protection during Clostridium difficile infection. Nat Commun. 2019;10:2712

    PubMed  PubMed Central  Google Scholar 

  93. Garrido-Mesa N, Schroeder JH, Stolarczyk E et al. T-bet controls intestinal mucosa immune responses via repression of type 2 innate lymphoid cell function. Mucosal Immunol. 2019;12:51–63

    CAS  PubMed  Google Scholar 

  94. Sepahi A, Liu Q, Friesen L, Kim CH. Dietary fiber metabolites regulate innate lymphoid cell responses. Mucosal Immunol. 2020.

  95. Lloyd-Price J, Arze C, Ananthakrishnan AN et al. Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases. Nature. 2019;569:655–662

    CAS  PubMed  PubMed Central  Google Scholar 

  96. Lamas B, Richard ML, Leducq V et al. CARD9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligands. Nat Med. 2016;22:598–605

    CAS  PubMed  PubMed Central  Google Scholar 

  97. Scott SA, Fu J, Chang PV. Microbial tryptophan metabolites regulate gut barrier function via the aryl hydrocarbon receptor. Proc Natl Acad Sci USA 2020;117:19376–19387

    CAS  PubMed  PubMed Central  Google Scholar 

  98. Artis D, Spits H. The biology of innate lymphoid cells. Nature. 2015;517:293–301

    CAS  PubMed  Google Scholar 

  99. Sano T, Huang W, Hall JA et al. An IL-23R/IL-22 circuit regulates epithelial serum amyloid A to promote local effector Th17 responses. Cell. 2015;163:381–393

    CAS  PubMed  PubMed Central  Google Scholar 

  100. Atarashi K, Tanoue T, Ando M et al. Th17 cell induction by adhesion of microbes to intestinal epithelial cells. Cell. 2015;163:367–380

    CAS  PubMed  PubMed Central  Google Scholar 

  101. Mielke LA, Jones SA, Raverdeau M et al. Retinoic acid expression associates with enhanced IL-22 production by gammadelta T cells and innate lymphoid cells and attenuation of intestinal inflammation. J Exp Med. 2013;210:1117–1124

    CAS  PubMed  PubMed Central  Google Scholar 

  102. Longman RS, Diehl GE, Victorio DA et al. CX(3)CR1(+) mononuclear phagocytes support colitis-associated innate lymphoid cell production of IL-22. J Exp Med. 2014;211:1571–1583

    CAS  PubMed  PubMed Central  Google Scholar 

  103. Castellanos JG, Woo V, Viladomiu M et al. Microbiota-induced TNF-like ligand 1A drives group 3 innate lymphoid cell-mediated barrier protection and intestinal T cell activation during colitis. Immunity. 2018;49:e5

    Google Scholar 

  104. Mortha A, Chudnovskiy A, Hashimoto D et al. Microbiota-dependent crosstalk between macrophages and ILC3 promotes intestinal homeostasis. Science. 2014;343:1249288

    PubMed  PubMed Central  Google Scholar 

  105. Levy M, Thaiss CA, Zeevi D et al. Microbiota-modulated metabolites shape the intestinal microenvironment by regulating NLRP6 inflammasome signaling. Cell. 2015;163:1428–1443

    CAS  PubMed  PubMed Central  Google Scholar 

  106. Munoz M, Eidenschenk C, Ota N et al. Interleukin-22 induces interleukin-18 expression from epithelial cells during intestinal infection. Immunity. 2015;42:321–331

    CAS  PubMed  Google Scholar 

  107. Hepworth MR, Fung TC, Masur SH et al. Group 3 innate lymphoid cells mediate intestinal selection of commensal bacteria-specific CD4(+) T cells. Science. 2015;348:1031–1035

    CAS  PubMed  PubMed Central  Google Scholar 

  108. Hepworth MR, Monticelli LA, Fung TC et al. Innate lymphoid cells regulate CD4+ T-cell responses to intestinal commensal bacteria. Nature. 2013;498:113–117

    CAS  PubMed  PubMed Central  Google Scholar 

  109. Neurath MF. Current and emerging therapeutic targets for IBD. Nat Rev Gastroenterol Hepatol. 2017;14:269–278

    CAS  PubMed  Google Scholar 

  110. Withers DR, Hepworth MR, Wang X et al. Transient inhibition of ROR-gammat therapeutically limits intestinal inflammation by reducing TH17 cells and preserving group 3 innate lymphoid cells. Nat Med. 2016;22:319–323

    CAS  PubMed  PubMed Central  Google Scholar 

  111. Hueber W, Sands BE, Lewitzky S et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012;61:1693–1700

    CAS  PubMed  Google Scholar 

  112. Withers DR, Hepworth MR. Group 3 innate lymphoid cells: communications hubs of the intestinal immune system. Front Immunol. 2017;8:1298

    PubMed  PubMed Central  Google Scholar 

  113. Kaser A. Not all monoclonals are created equal-lessons from failed drug trials in Crohn’s disease. Best Pract Res Clin Gastroenterol. 2014;28:437–449

    CAS  PubMed  Google Scholar 

  114. Colombel JF, Sendid B, Jouault T, Poulain D. Secukinumab failure in Crohn’s disease: the yeast connection? Gut. 2013;62:800–801

    CAS  PubMed  Google Scholar 

  115. Zhou L, Sonnenberg GF. Essential immunologic orchestrators of intestinal homeostasis. Sci Immunol. 2018;3.

  116. Sandborn WJ, Ferrante M, Bhandari BR, et al. Efficacy and safety of mirikizumab in a randomized phase 2 study of patients with ulcerative colitis. Gastroenterology. 2019.

  117. Geremia A, Arancibia-Carcamo CV. Innate lymphoid cells in intestinal inflammation. Front Immunol. 2017;8:1296

    PubMed  PubMed Central  Google Scholar 

  118. Tang C, Kakuta S, Shimizu K, et al. Suppression of IL-17F, but not of IL-17A, provides protection against colitis by inducing Treg cells through modification of the intestinal microbiota. Nat Immunol. 2018.

  119. Reinisch W, de Villiers W, Bene L et al. Fontolizumab in moderate to severe Crohn’s disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study. Inflamm Bowel Dis. 2010;16:233–242

    PubMed  Google Scholar 

  120. Goldberg R, Prescott N, Lord GM, MacDonald TT, Powell N. The unusual suspects–innate lymphoid cells as novel therapeutic targets in IBD. Nat Rev Gastroenterol Hepatol. 2015;12:271–283

    CAS  PubMed  Google Scholar 

  121. Rutgeerts P, Sandborn WJ, Feagan BG et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462–2476

    CAS  PubMed  Google Scholar 

  122. Pelczar P, Witkowski M, Perez LG et al. A pathogenic role for T cell-derived IL-22BP in inflammatory bowel disease. Science. 2016;354:358–362

    CAS  PubMed  Google Scholar 

  123. Danese S, Vermeire S, Hellstern P et al. Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn’s disease (ANDANTE I and II). Gut. 2019;68:40–48

    CAS  PubMed  Google Scholar 

  124. Powell N, Walker AW, Stolarczyk E et al. The transcription factor T-bet regulates intestinal inflammation mediated by interleukin-7 receptor+ innate lymphoid cells. Immunity. 2012;37:674–684

    CAS  PubMed  PubMed Central  Google Scholar 

  125. Ermann J, Staton T, Glickman JN, de Waal Malefyt R, Glimcher LH. Nod/Ripk2 signaling in dendritic cells activates IL-17A-secreting innate lymphoid cells and drives colitis in T-bet-/-.Rag2-/- (TRUC) mice. Proc Natl Acad Sci USA. 2014;111:E2559-66.

Download references

Acknowledgment

This manuscript preparation was supported by the National Natural Science Foundation of China (grant no. 81970494 and 81670504) and Key Research and Development Program of Hunan Province (grant no. 2019SK2041).

Author information

Authors and Affiliations

  1. Department of Gastroenterology, The Third Xiangya Hospital of Central South University, Tongzipo Road, Changsha, 410013, Hunan, China

    Weiwei Luo, Li Tian, Zhaohua Shen, Mengwei Xiao, Shuai Wu, Xiangrui Meng, Xing Wu & Xiaoyan Wang

  2. Hunan Key Laboratory of Non-Resolving Inflammation and Cancer, Xiangya Road, Changsha, 410008, Hunan, China

    Weiwei Luo, Zhaohua Shen, Mengwei Xiao, Shuai Wu, Xiangrui Meng, Xing Wu & Xiaoyan Wang

  3. Department of Gastroenterology, The First Hospital of Changsha Medical University, Yingpan Road, Changsha, 410005, Hunan, China

    Bei Tan

Authors
  1. Weiwei Luo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Li Tian
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bei Tan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Zhaohua Shen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mengwei Xiao
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shuai Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Xiangrui Meng
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Xing Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Xiaoyan Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xiaoyan Wang.

Ethics declarations

Conflict of interest

The authors declare no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Luo, W., Tian, L., Tan, B. et al. Update: Innate Lymphoid Cells in Inflammatory Bowel Disease. Dig Dis Sci 67, 56–66 (2022). https://doi.org/10.1007/s10620-021-06831-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-021-06831-8

Keywords

Search

Navigation